Tiziana Life Sciences (TLSA) announced the expansion of its Phase 2 clinical trial evaluating intranasal foralumab for non-active secondary progressive multiple sclerosis, SPMS. The trial sites ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results